

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

14 August 2024

**IXICO plc
("IXICO" or the "Company")**

Long term contract win for a study in Huntington's Disease

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, is pleased to announce that it has been contracted by a US based pharma client to provide its imaging biomarker services for a Phase 1/2 clinical trial for patients with Huntington's Disease (HD). The trial is expected to run for up to ten years and contribute close to £2m to the Company's order book.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"IXICO's expertise in providing advanced imaging biomarkers and radiological reads for HD is widely recognised. We are delighted to be awarded this new contract and look forward to support our client's efforts in this important HD development programme."

For further information please contact:

IXICO plc

Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer

+44 (0) 20 3763 7499

**Cavendish Capital Markets Limited (Nominated Adviser and
Sole Broker)**

Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks/Harriet Ward (Corporate Broking)
Michael F Johnson / Tamar Cranford Smith (Sales)

+44 (0) 20 7220 0500

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

